Asianet News English

Johnson & Johnson’s single-shot COVID-19 vaccine shows strong activity against Delta variant

Data showed that the durability of the immune response lasted through at least eight months, the US-based healthcare company said, adding that its vaccine was 85% effective and could also help prevent hospitalization and death.

Johnson & Johnsons single-shot COVID-19 vaccine shows strong activity against Delta variant-dnm
Author
Bengaluru, First Published Jul 2, 2021, 3:08 PM IST
  • Facebook
  • Twitter
  • Whatsapp

Johnson & Johnson said late Thursday that its single-shot Covid-19 vaccine generated strong, persistent activity against the Delta and other highly prevalent variants.

Data showed that the durability of the immune response lasted through at least eight months, the US-based healthcare company said, adding that its vaccine was 85% effective and could also help prevent hospitalization and death.

“Current data for the eight months studied so far shows that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time,” Mathai Mammen, head of research & development at J&J’s drugs business, said in the statement.

The Covid-19 vaccine elicited neutralizing antibody activity against the Delta variant, first identified in India, at an even higher level than what was observed for the Beta variant, which was first detected in South Africa, the company said.

J&J has submitted data as a preprint to the website bioRxiv ahead of peer review.

Johnson & Johnson's single-dose Covid-19 vaccine was 85% effective against severe/critical disease and demonstrated protection against hospitalization and death. The vaccine was consistently effective across all regions studied globally, including in South Africa and Brazil, where there was a high prevalence of rapidly emerging Beta and Zeta (P.2) variants during the study period.

A single dose of the Johnson & Johnson Covid-19 vaccine generated neutralizing antibodies against a range of SARS-CoV-2 variants of concern, which increased over time (the average neutralizing titer at eight months exceeded that average at 29 days), including against the increasingly prevalent and more transmissible Delta (B.1.617.2) variant, the partially neutralization-resistant Beta (B.1.351), the Gamma (P.1) variants and others, including the Alpha (B.1.1.7), Epsilon (B.1.429), Kappa (B.1.617.1) and D614G variants, as well as the original SARS-CoV-2 strain (WA1/2020).

NOTE: Asianet News humbly requests everyone to wear masks, sanitize, maintain social distancing and get vaccinated as soon as eligible. Together we can and will break the chain #ANCares #IndiaFightsCorona 

Follow Us:
Download App:
  • android
  • ios